Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile

June 25, 2024

https://www.globenewswire.com/news-release/2024/06/25/2904125/0/en/Allakos-Announces-Positive-Results-from-its-Ongoing-Phase-1-Trial-of-AK006-in-Healthy-Volunteers-with-AK006-Demonstrating-High-Receptor-Occupancy-on-Mast-Cells-and-a-Favorable-Safe.html

– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –
– Skin biopsies from subjects treated with AK006 show high receptor occupancy –
– AK006 was well-tolerated with a favorable safety profile –

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.